Posted 12/6/2019 5:32 AM (GMT -7)
Thanks for the link. Good read.
For reference for others and a question, their conclusions were:
“Na18F PET/CT is the most comprehensive bone imaging modality for evaluating osseous metastatic disease. Although there is a need for additional cost-benefit analyses for this modality, increasing availability and evolving reimbursement structures will likely continue to increase the attractiveness of Na18F PET/CT in routine patient management. In addition, emerging data suggest that the high target-to-background signal ratio of Na18F PET and advances in low-dose CT technologies may allow further dose reductions for Na18F PET/CT to levels similar to or below those of 99mTc-MDP bone scintigraphy with SPECT. Furthermore, re- cent studies suggest the potential viability of combined Na18F and FDG PET/CT, in some cohorts, for single-session staging of soft tissue and osseous disease, which may provide improved patient convenience and partial mitigation of imaging costs by avoiding acquisition of sequential imaging studies.”
I‘ve always thought the FDG wasn’t very appropriate for PC. This may change my mind. And, I’m wondering - are they saying that a FDG can be done at the same time as the f18?
I’ve had a PSMA through a study a few years ago at NIH. The f18 identified a bone met where the PSMA did not. Not sure if that was because it was an earlier PSMA agent or I’m not sensitive to PSMA.
It’s tough to change old habits, and I’m so used to getting the f18...but probably should be looking it to these other scans more closely...perhaps Auximim or another PSMA.